Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Dog DNA Plays Role in Developing New Human Therapies

By Drug Discovery Trends Editor | March 18, 2014

Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a proof-of-concept study led by the National Cancer Institute (NCI) and the Translational Genomics Research Institute (TGen).
 
Pure-breed dogs, whose genetics have been standardized by hundreds of years of human intervention, provide highly predictable genetic models useful in designing clinical trials, in which specific drugs are matched to the molecular profiles of human patients, according to the study published in the scientific journal PLOS ONE.
 
“Our canine companions are not only ‘Man’s Best Friend,’ but our study shows that dogs also can help human patients pursue battles against various types of cancer,” said Dr. Jeffrey Trent, TGen president and research director, and the study’s senior author. “Not only do dogs with cancer benefit from this research, but people do, as well.”
 
While there are, relatively, many genetic differences among humans with the same type of cancer, there are far fewer genetic differences among dogs of the same breed, making it vastly easier to identify and study the genes driving canine cancers.
 
The process of integrating naturally occurring cancers in dogs into the general studies of human cancer biology and therapy is known as comparative oncology. The identification of specific drugs to treat individuals based on their specific genetic or molecular make-up is often referred to as personalized medicine, or PMed.
 
Genetic samples from 31 dogs were analyzed in the proof-of-concept study organized under NCI’s Comparative Oncology Trials Consortium (COTC). Genetic samples were derived for this study from tumor biopsy samples. No dogs were harmed in any way in this clinical study.
 
“Complex models are needed to effectively evaluate PMed study designs, and this proof-of-concept trial validates the dog with cancer as a model for clinical evaluation of novel PMed approaches,” said Dr. Melissa Paoloni, the study’s lead author and former director of the COTC. “Comparative oncology models have the potential to expedite this evaluation and lead advancements in personalized medicine.”
 
The COTC study was organized according to the propensity of different breeds to develop particular types of cancer. The study included Scottish terriers with bladder transitional cell carcinoma, golden retrievers with lymphoma, American cocker spaniels with melanoma, and a fourth group of dogs open to all cancer types.
 
The study’s 31 samples of dog tumors was compared to 40 normal canine tissues samples as a way of estimating the variance in gene expression. The target turnaround time for this analysis was seven days, but the study averaged this process in less than five days.
 
“Overall the turnaround for sample analyses fit a relevant clinical window for future comparative oncology trials to model human PMed advancements,” said Dr. William Hendricks, a TGen Staff Scientist and another author of the study. “Future comparative oncology studies, optimizing the delivery of PMed strategies, may aid cancer drug development.”
 
“Data from this study serves as rationale to now include dogs with spontaneous cancers in the advancement and optimization of PMed for human patients,” according to the study, Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.  
 
Date: March 17, 2014
Source: Translational Genomics Research Institute

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE